Short Interest in Opus Genetics Surges 81%

Shares of the biotech company have seen a significant increase in short positions over the past month.

Mar. 27, 2026 at 9:23am

Got story updates? Submit your updates here. ›

Opus Genetics, Inc. (NASDAQ:IRD), a clinical-stage ophthalmic biopharmaceutical company, has seen a substantial 81.3% increase in short interest during March. As of March 13th, there were 2,014,121 shares sold short, up from 1,110,696 shares at the end of February. With an average daily trading volume of 1,322,364 shares, the short-interest ratio currently stands at 1.5 days.

Why it matters

The surge in short interest suggests that some investors are betting against Opus Genetics' stock performance, potentially indicating concerns about the company's prospects or the broader market conditions. This development is noteworthy as it could impact the stock's volatility and trading activity in the near term.

The details

Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company's stock has seen significant price fluctuations in recent months, with the share price ranging from a 52-week low of $0.65 to a high of $5.30.

  • As of March 13th, 2023, there was short interest totaling 2,014,121 shares.
  • This represents an increase of 81.3% from the February 26th total of 1,110,696 shares.

The players

Opus Genetics, Inc.

A clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders.

Got photos? Submit your photos here. ›

The takeaway

The surge in short interest in Opus Genetics' stock suggests that some investors are bearish on the company's prospects, which could lead to increased volatility in the stock's trading. However, the company's focus on developing innovative treatments for eye disorders may still attract investor interest, and its stock performance will likely be closely watched in the coming months.